GSK gives update on RSV maternal vaccine candidate
Issued: 18 February 2022, London UK
GSK provides update on phase III RSV maternal vaccine candidate programme
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has voluntarily paused enrolment and vaccination in the GRACE phase III trial (NCT04605159), evaluating its potential respiratory syncytial virus (RSV) maternal vaccine candidate, as well as two other trials investigating this candidate in pregnant women (NCT04980391, NCT05229068).
This decision was made following a recommendation from the Independent Data Monitoring Committee based on an observation from a routine safety assessment. Monitoring safety signals is an integral part of the clinical development process for potential new vaccines.
This decision does not impact the ongoing AReSVi 006 phase III trial (NCT04886596) for RSV older adults (60 years and above). This trial remains on track with an anticipated data readout in the first half of 2022.
The Company will provide a further update on the RSV maternal vaccine candidate in due course.
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us .
|
GSK enquiries: |
|
|
|
|
Media enquiries: |
Tim Foley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Simon Moore |
+44 (0) 20 8047 5502 |
(London) |
|
|
Kristen Neese |
+1 804 217 8147 |
(Philadelphia) |
|
|
Kathleen Quinn |
+1 202 603 5003 |
(Washington DC) |
|
|
Evan Berland |
+1 215 432 0234 |
(Philadelphia) |
|
|
|
|
|
|
Analyst/Investor enquiries: |
Nick Stone |
+44 (0) 7717 618834 |
(London) |
|
|
Sonya Ghobrial |
+44 (0) 7392 784784 |
(Consumer) |
|
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
|
Mick Readey |
+44 (0) 7990 339653 |
(London) |
|
|
Josh Williams |
+44 (0) 7385 415719 |
(London) |
|
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
|
|
Frannie DeFranco |
+1 215 751 4855 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2020, GSK's 2021 Q4 Results and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
COMPANIES COVERED:
Latest directors dealings
- 2 days ago FRP Advisory Group
- 2 days ago Marks Electrical Group
- 2 days ago CLS Holdings
- 2 days ago QinetiQ Group
- 2 days ago Spectris